Nilo Therapeutics
New York, US · Founded 2024 · Delaware corporation · 5 known investors
Biotech
Founders & leadership
JG
Jeff GoaterExecutive
Board
TK
Tim KutzkeyBoard director
Investors · 5
DCVC (Data Collective)Palo Alto · $5M – $25M
DCVC Bioreported · 2 sourcesPalo Alto
Lux Capitalreported · 2 sourcesNew York · $100K – $100M
The Column Groupreported · 2 sourcesSan Francisco · $30M
Also in the syndicate · 1
Gates Foundation
Funding
SEC filings, press & company announcements$110.6M disclosed across 2 rounds · 2024–2025
- $101MSeries AOct 2025 · 2 sources
DCVC Bio (lead), Lux Capital (lead), The Column Group (lead), Alexandria Venture Investments, Gates Foundation
Source ↗
▶$9.6MraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$9.6MraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tim KutzkeyExecutive Officer, Director, Promoter
- Jeff GoaterExecutive Officer, Director
- Offering amount
- $101M
- Amount sold
- $9.6M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Nilo Therapeutics's investors?
- Nilo Therapeutics's investors include DCVC (Data Collective), DCVC Bio, Lux Capital, The Column Group.
- How much funding has Nilo Therapeutics raised?
- Nilo Therapeutics has disclosed $110.6M raised across 2 rounds.
- Where is Nilo Therapeutics headquartered?
- Nilo Therapeutics is headquartered in New York, US.